The Posterior Pituitary

The Pituitary

Volumn , Issue , 2011, Pages 261-299

  Bichet, Daniel G ^a  

^a HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84860917025     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-380926-1.10008-2     Document Type: Chapter

References (310)

1. Wilson Y., Nag N., Davern P., Oldfield B.J., McKinley M.J., Greferath U., et al. Visualization of functionally activated circuitry in the brain. Proc Nat Acad Sci USA 2002, 99:3252-3257.
2. Sofroniew M.V. Morphology of vasopressin and oxytocin neurones and their central and vascular projections. The Neurohypophysis: Structure, Function, and Control 1983, 101-114. Elsevier, New York. L. Cross (Ed.).
3. Kalogeras K.T., Nieman L.N., Friedman T.C., Doppman J.L., Cutler G.B.J., Chrousos G.P., et al. Inferior petrosal sinus sampling in healthy human subjects reveals a unilateral corticotropin-releasing hormone-induced arginine vasopressin release associated with ipsilateral adrenocorticotropin secretion. J Clin Invest 1996, 97:2045-2050.
4. Yanovski J.A., Friedman T.C., Nieman L.K., Chrousos G.P., Cutler G.B., Doppman J.L., et al. Inferior petrosal sinus AVP in patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1997, 47:199-206.
5. Renaud L.P., Bourque C.W., Day T.A., Ferguson A.V., Randle J.C.R. Electrophysiology of mammalian hypothalamic supraoptic and paraventricular neurosecretory cells. The Electrophysiology of the Secretory Cell 1985, 165-194. Elsevier, New York. A.M. Poisner, J.M. Trifaro (Eds.).
6. Bourque C.W. Central mechanisms of osmosensation and systemic osmoregulation. Nat Rev Neurosci 2008, 9:519-531.
7. Donaldson Z.R., Young L.J. Oxytocin, vasopressin, and the neurogenetics of sociality. Science 2008, 322:900-904.
8. Gwee P.C., Amemiya C.T., Brenner S., Venkatesh B. Sequence and organization of coelacanth neurohypophysial hormone genes: Evolutionary history of the vertebrate neurohypophysial hormone gene locus. BMC Evol Biol 2008, 8:93.
9. Venkatesh B., Si-Hoe S.L., Murphy D., Brenner S. Transgenic rats reveal functional conservation of regulatory controls between the Fugu isotocin and rat oxytocin genes. Proc Nat Acad Sci USA 1997, 94:12462-12466.
10. Tessmar-Raible K., Raible F., Christodoulou F., Guy K., Rembold M., Hausen H., et al. Conserved sensory-neurosecretory cell types in annelid and fish forebrain: Insights into hypothalamus evolution. Cell 2007, 129:1389-1400.
11. Burbach J.P., Luckman S.M., Murphy D., Gainer H. Gene regulation in the magnocellular hypothalamo-neurohypophysial system. Physiol Rev 2001, 81:1197-1267.
12. Rao V.V., Loffler C., Battey J., Hansmann I. The human gene for oxytocin-neurophysin I (OXT) is physically mapped to chromosome 20p13 by in situ hybridization. Cytogenet Cell Genet 1992, 61:271-273.
13. Chen L., Rose J.P., Breslow E., Yang D., Chang W.R., Furey W.F.J., et al. Crystal structure of a bovine neurophysin II dipeptide complex at 2.8 Angström determined from the single-wave length anomalous scattering signal of an incorporated iodine atom. Proc Nat Acad Sci USA 1991, 88:4240-4244.
14. Insel T.R. The challenge of translation in social neuroscience: A review of oxytocin, vasopressin, and affiliative behavior. Neuron 2010, 65:768-779.
15. Huber D., Veinante P., Stoop R. Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science 2005, 308:245-248.
16. Valtin H., North W.G., Edwards B.R., Gellai M. Animal models of diabetes insipidus. Front Horm Res 1985, 13:105-126.
17. Schmale H., Richter D. Single base deletion in the vasopressin gene is the cause of diabetes insipidus in Brattleboro rats. Nature 1984, 308:705-709.
18. Schmale H., Bahnsen U., Fehr S., Nahke P., Richter D. Hereditary diabetes insipidus in man and rat. Vasopressin 1991, 57-62. Colloques INSERM/John Libbey Eurotext, Paris. S. Jard, R. Jamison (Eds.).
19. Richter D. Reflections on central diabetes insipidus: Retrospective and perspectives. Vasopressin 1993, 3-14. John Libbey Eurotext, Paris. P. Gross, D. Richter, G.L. Robertson (Eds.).
20. Serradeil-Le Gal C., Lacour C., Valette G., Garcia G., Foulon L., Galindo G., et al. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest 1996, 98:2729-2738.
21. Jean-Alphonse F., Perkovska S., Frantz M.C., Durroux T., Mejean C., Morin D., et al. Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 2009, 20:2190-2203.
22. Evans D.A., De Bree F.M., Nijenhuis M., Van Der Kleij A.A., Zalm R., Korteweg N., et al. Processing of frameshifted vasopressin precursors. J Neuroendocrinol 2000, 12:685-693.
23. Balment R.J., Brimble M.J., Forsling M.L. Oxytocin release and renal actions in normal and Brattleboro rats. Ann NY Acad Sci US 1982, 394:241-253.
24. Chou C.L., DiGiovanni S.R., Luther A., Lolait S.J., Knepper M.A. Oxytocin as an antidiuretic hormone II. Role of V2 vasopressin receptor. Am J Physiol 1995, 269(Renal Fluid Electrolyte Physiol 38):F78-F85.
25. Repaske D.R., Phillips J.A., Kirby L.T., Tze W.J., D'Ercole A.J., Battey J. Molecular analysis of autosomal dominant neurohypophyseal diabetes insipidus. J Clin Endocrinol Metab 1990, 70:752-757.
26. McKusick V.A. Online Mendelian Inheritance in Man OMIM, (TM) 2000, McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD, World Wide Web URL: http://www.ncbi.nlm.nih.gov/omim/. 2000.
27. Christensen J.H., Rittig S. Familial neurohypophyseal diabetes insipidus - an update. Semin Nephrol 2006, 26:209-223.
28. Birk J., Friberg M.A., Prescianotto-Baschong C., Spiess M., Rutishauser J. Dominant pro-vasopressin mutants that cause diabetes insipidus form disulfide-linked fibrillar aggregates in the endoplasmic reticulum. J Cell Sci 2009, 122:3994-4002.
29. Abu Libdeh A., Levy-Khademi F., Abdulhadi-Atwan M., Bosin E., Korner M., et al. Autosomal recessive familial neurohypophyseal diabetes insipidus: Onset in early infancy. Eur J Endocrinol 2009, 162:221-226.
30. Hedrich C.M., Zachurzok-Buczynska A., Gawlik A., Russ S., Hahn G., et al. Autosomal dominant neurohypophyseal diabetes insipidus in two families. Molecular analysis of the vasopressin-neurophysin II gene and functional studies of three missense mutations. Horm Res 2009, 71:111-119.
31. Cool D.R., Jackson S.B., Waddell K.S. Structural requirements for sorting pro-vasopressin to the regulated secretory pathway in a neuronal cell line. Open Neuroendocrinol J 2008, 1:1-8.
32. Christensen J.H., Siggaard C., Corydon T.J., Robertson G.L., Gregersen N., Bolund L., et al. Differential cellular handling of defective arginine vasopressin (AVP) prohormones in cells expressing mutations of the AVP gene associated with autosomal dominant and recessive familial neurohypophyseal diabetes insipidus. J Clin Endocrinol Metab 2004, 89:4521-4531.
33. Ito M., Jameson J.L., Ito M. Molecular basis of autosomal dominant neurohypophyseal diabetes insipidus. Cellular toxicity caused by the accumulation of mutant vasopressin precursors within the endoplasmic reticulum. J Clin Invest 1997, 99:1897-1905.
34. Castino R., Isidoro C., Murphy D. Autophagy-dependent cell survival and cell death in an autosomal dominant familial neurohypophyseal diabetes insipidus in vitro model. FASEB J 2005, 19:1024-1026.
35. Gregersen N., Bross P., Vang S., Christensen J.H. Protein misfolding and human disease. Annu Rev Genomics Hum Genet 2006, 7:103-124.
36. Bichet D.G., Arthus M.-F., Lonergan M., Morgan K., Fujiwara T.M. Hereditary central diabetes insipidus: Autosomal dominant and autosomal recessive phenotypes due to mutations in the prepro-AVP-NPII gene. J Am Soc Nephrol 1998, 9:386A.
37. Willcutts M.D., Felner E., White P.C. Autosomal recessive familial neurohypophyseal diabetes insipidus with continued secretion of mutant weakly active vasopressin. Hum Mol Genet 1999, 8:1303-1307.
38. Schally A.V. Hormones of the neurohypophysis. The Hypothalamus and Pituitary in Health and Disease 1972, 154-171. Charles C Thomas, Springfield. W. Lock, A.V. Schally (Eds.).
39. Schally A.V., Bowers C.Y., Kuroshima A., Ishida Y., Carter W.H., Redding T.W. Effect of lysine vasopressin dimers on blood pressure and some endocrine functions. Am J Physiol 1964, 207:378-384.
40. Acher R., Chauvet J. Structure, processing and evolution of the neurohypophysial hormone-neurophysin precursors. Biochimie 1988, 70:1197-1207.
41. Proux J.P. The arginine vasopressin-like insect diurectic hormone. Vasopressin 1991, 367-373. Colloques INSERM/John Libbey Eurotext, Paris. S. Jard, R. Jamison (Eds.).
42. Sachs H., Fawcett P., Takabatake Y., Portanova R. Biosynthesis and release of vasopressin and neurophysin. Recent Prog Horm Res 1969, 25:447-491.
43. Gainer H., Sarne Y., Brownstein M.J. Biosynthesis and axonal transport of rat neurohypophysial proteins and peptides. J Cell Biol 1977, 73:366-381.
44. Russell J.T., Brownstein M.J., Gainer H. Biosynthesis of vasopressin, oxytocin, and neurophysins: Isolation and characterization of two common precursors (propressophysin and prooxyphysin). Endocrinology 1980, 107:1880-1891.
45. Bichet D.G., Arthus M.F., Lonergan M. Platelet vasopressin receptors in patients with congenital nephrogenic diabetes insipidus. Kidney Int 1991, 39:693-699.
46. Share L., Crofton J.T., Brooks D.P., Chesney C.M. Platelet and plasma vasopressin in dog during hydration and vasopressin infusion. Am J Physiol 1985, 249:R313-R316.
47. Anfossi G., Mularoni E., Trovati M., Massucco P., Mattiello L., Emanuelli G. Arginine vasopressin release from human platelets after irreversible aggregation. Clin Sci (Colch) 1990, 78:113-116.
48. Sawchenko P.E., Swanson L.W. The organization of noradrenergic pathways from the brainstem to the paraventricular and supraoptic nuclei in the rat. Brain Res 1982, 257:275-325.
49. Randle J.C., Mazurek M., Kneifel D., Dufresne J., Renaud L.P. Alpha 1-adrenergic receptor activation releases vasopressin and oxytocin from perfused rat hypothalamic explants. Neurosci Lett 1986, 65:219-223.
50. Day T.A., Randle J.C., Renaud L.P. Opposing alpha- and beta-adrenergic mechanisms mediate dose-dependent actions of noradrenaline on supraoptic vasopressin neurones in vivo. Brain Res 1985, 358:171-179.
51. Mason W.T., Ho Y.W., Eckenstein F., Hatton G.I. Mapping of cholinergic neurons associated with rat supraoptic nucleus: Combined immunocytochemical and histochemical identification. Brain Res Bull 1983, 11:617-626.
52. Ferguson A.V., Renaud L.P. Systemic angiotensin acts at subfornical organ to facilitate activity of neurohypophysial neurons. Am J Physiol 1986, 251:R712-R717.
53. Watson S.J., Akil H., Fischli W., Goldstein A., Zimmerman E., Nilaver G., et al. Dynorphin and vasopressin: Common localization in magnocellular neurons. Science 1982, 216:85-87.
54. Simantov R., Snyder S.H. Opiate receptor binding in the pituitary gland. Brain Res 1977, 124:178-184.
55. Edwards A.M., Mann M.E., Marfell-Jones M.J., Rankin D.M., Noakes T.D., Shillington D.P. Influence of moderate dehydration on soccer performance: Physiological responses to 45 min of outdoor match-play and the immediate subsequent performance of sport-specific and mental concentration tests. Br J Sports Med 2007, 41:385-391.
56. Saat M., Sirisinghe R.G., Singh R., Tochihara Y. Effects of short-term exercise in the heat on thermoregulation, blood parameters, sweat secretion and sweat composition of tropic-dwelling subjects. J Physiol Anthropol Appl Human Sci 2005, 24:541-549.
57. Shirreffs S.M., Merson S.J., Fraser S.M., Archer D.T. The effects of fluid restriction on hydration status and subjective feelings in man. Br J Nutr 2004, 91:951-958.
58. Geelen G., Greenleaf J.E., Keil L.C. Drinking-induced plasma vasopressin and norepinephrine changes in dehydrated humans. J Clin Endocrinol Metab 1996, 81:2131-2135.
59. Andersen L.J., Jensen T.U., Bestle M.H., Bie P. Gastrointestinal osmoreceptors and renal sodium excretion in humans. Am J Physiol Regul Integr Comp Physiol 2000, 278:R287-R294.
60. Claybaugh J.R., Sato A.K., Crosswhite L.K., Hassell L.H. Effects of time of day, gender, and menstrual cycle phase on the human response to a water load. Am J Physiol Regul Integr Comp Physiol 2000, 279:R966-R973.
61. Verney E. The antidiuretic hormone and the factors which determine its release. Proc R Soc London Ser B 1947, 135:25-26.
62. Kuramochi G., Kobayashi I. Regulation of the urine concentration mechanism by the oropharyngeal afferent pathway in man. Am J Nephrol 2000, 20:42-47.
63. Choi-Kwon S., Baertschi A.J. Splanchnic osmosensation and vasopressin: Mechanisms and neural pathways. Am J Physiol 1991, 261:E18-E25.
64. Egan G., Silk T., Zamarripa F., Williams J., Federico P., Cunnington R., et al. Neural correlates of the emergence of consciousness of thirst. Proc Nat Acad Sci USA 2003, 100:15241-15246.
65. Stricker E.M., Hoffmann M.L. Presystemic signals in the control of thirst, salt appetite, and vasopressin secretion. Physiol Behav 2007, 91:404-412.
66. Huang W., Sved A.F., Stricker E.M. Water ingestion provides an early signal inhibiting osmotically stimulated vasopressin secretion in rats. Am J Physiol Regul Integr Comp Physiol 2000, 279:R756-R760.
67. Osaka T., Kobayashi A., Inoue S. Vago-sympathoadrenal reflex in thermogenesis induced by osmotic stimulation of the intestines in the rat. J Physiol 2002, 540:665-671.
68. McKinley M.J., McAllen R.M., Davern P., Giles M.E., Penschow J., Sunn N., et al. The sensory circumventricular organs of the mammalian brain. Adv Anat Embryol Cell Biol 2003, 172(III-XII):1-122.
69. Thrasher T.N., Keil L.C., Ramsay D.J. Lesions of the organum vasculosum of the lamina terminalis (OVLT) attenuate osmotically-induced drinking and vasopressin secretion in the dog. Endocrinology 1982, 110:1837-1839.
70. 2+ contrasted T1-weighted MRI. Auton Neurosci 2004, 113:43-54.
71. McKinley M.J., Denton D.A., Oldfield B.J., De Oliveira L.B., Mathai M.L. Water intake and the neural correlates of the consciousness of thirst. Semin Nephrol 2006, 26:249-257.
72. Ciura S., Bourque C.W. Transient receptor potential vanilloid 1 is required for intrinsic osmoreception in organum vasculosum lamina terminalis neurons and for normal thirst responses to systemic hyperosmolality. J Neurosci 2006, 26:9069-9075.
73. Anderson J.W., Washburn D.L., Ferguson A.V. Intrinsic osmosensitivity of subfornical organ neurons. Neuroscience 2000, 100:539-547.
74. Oliet S.H., Bourque C.W. Properties of supraoptic magnocellular neurones isolated from the adult rat. J Physiol 1992, 455:291-306.
75. Oliet S.H., Bourque C.W. Mechanosensitive channels transduce osmosensitivity in supraoptic neurons. Nature 1993, 364:341-343.
76. Mason W.T. Supraoptic neurones of rat hypothalamus are osmosensitive. Nature 1980, 287:154-157.
77. Bourque C.W. Ionic basis for the intrinsic activation of rat supraoptic neurones by hyperosmotic stimuli. J Physiol 1989, 417:263-277.
78. Qiu D.L., Shirasaka T., Chu C.P., Watanabe S., Yu N.S., Katoh T., et al. Effect of hypertonic saline on rat hypothalamic paraventricular nucleus magnocellular neurons in vitro. Neurosci Lett 2004, 355:117-120.
79. Oliet S.H., Bourque C.W. Steady-state osmotic modulation of cationic conductance in neurons of rat supraoptic nucleus. Am J Physiol 1993, 265:R1475-R1479.
80. Sharif Naeini R., Witty M.F., Seguela P., Bourque C.W. An N-terminal variant of Trpv1 channel is required for osmosensory transduction. Nat Neurosci 2006, 9:93-98.
81. Sharif-Naeini R., Ciura S., Bourque C.W. TRPV1 gene required for thermosensory transduction and anticipatory secretion from vasopressin neurons during hyperthermia. Neuron 2008, 58:179-185.
82. Cohen D.M. The transient receptor potential vanilloid-responsive 1 and 4 cation channels: Role in neuronal osmosensing and renal physiology. Curr Opin Nephrol Hypertens 2007, 16:451-458.
83. Tian W., Fu Y., Garcia-Elias A., Fernandez-Fernandez J.M., Vicente R., Kramer P.L., et al. A loss-of-function nonsynonymous polymorphism in the osmoregulatory TRPV4 gene is associated with human hyponatremia. Proc Nat Acad Sci USA 2009, 106:14034-14039.
84. Aubry R.H., Nankin H.R., Moses A.M., Streeten D.H. Measurement of the osmotic threshold for vasopressin release in human subjects, and its modification by cortisol. J Clin Endocrinol Metab 1965, 25:1481-1492.
85. Moses A.M., Streeten D.H. Differentiation of polyuric states by measurement of responses to changes in plasma osmolality induced by hypertonic saline infusions. Am J Med 1967, 42:368-377.
86. Moses A.M., Miller M., Streeten D.H. Quantitative influence of blood volume expansion on the osmotic threshold for vasopressin release. J Clin Endocrinol Metab 1967, 27:655-662.
87. Moses A.M., Miller M. Osmotic threshold for vasopressin release as determined by saline infusion and by dehydration. Neuroendocrinology 1971, 7:219-226.
88. Bichet D.G., Kortas C., Mettauer B., Manzini C., Marc-Aurele J., Rouleau J.L., et al. Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure. Kidney Int 1986, 29:1188-1196.
89. Bichet D.G., Arthus M.-F., Barjon J.N., Lonergan M., Kortas C. Human platelet fraction arginine-vasopressin. J Clin Invest 1987, 79:881-887.
90. Robertson G.L., Shelton R.L., Athar S. The osmoregulation of vasopressin. Kidney Int 1976, 10:25-37.
91. Hammer M., Ladefoged J., Olgaard K. Relationship between plasma osmolality and plasma vasopressin in human subjects. Am J Physiol 1980, 238:E313-E317.
92. Bie P. Osmoreceptors, vasopressin, and control of renal water excretion. Physiol Rev 1980, 60:961-1048.
93. Thompson C.J., Bland J., Burd J., Baylis P.H. The osmotic thresholds for thirst and vasopressin release are similar in healthy man. Clin Sci 1986, 71:651-656.
94. Robertson G.L. Abnormalities of thirst regulation. Kidney Int 1984, 25:460-469.
95. Thrasher T.N., Nistal-Herrera J.F., Keil L.C., Ramsay D.J. Satiety and inhibition of vasopressin secretion after drinking in dehydrated dogs. Am J Physiol 1981, 240:E394-E401.
96. Geelen G., Keil L.C., Kravik S.E., Wade C.E., Thrasher T.N., Barnes P.R., et al. Inhibition of plasma vasopressin after drinking in dehydrated humans. Am J Physiol 1984, 247:R968-R971.
97. Davison J.M., Shiells E.A., Philips P.R., Lindheimer M.D. Suppression of AVP release by drinking despite hypertonicity during and after gestation. Am J Physiol 1988, 254:F588-F592.
98. Salata R.A., Verbalis J.G., Robinson A.G. Cold water stimulation of oropharyngeal receptors in man inhibits release of vasopressin. J Clin Endocrinol Metab 1987, 65:561-567.
99. Zerbe R.L. Genetic factors in normal and abnormal regulation of vasopressin secretion. Vasopressin 1985, 213-220. Raven Press, New York. R.W. Schrier (Ed.).
100. Durr J.A., Stamoutsos B., Lindheimer M.D. Osmoregulation during pregnancy in the rat. Evidence for resetting of the threshold for vasopressin secretion during gestation. J Clin Invest 1981, 68:337-346.
101. Davison J.M., Gilmore E.A., Durr J., Robertson G.L., Lindheimer M.D. Altered osmotic thresholds for vasopressin secretion and thirst in human pregnancy. Am J Physiol 1984, 246:F105-F109.
102. Davison J.M., Shiells E.A., Philips P.R., Lindheimer M.D. Serial evaluation of vasopressin release and thirst in human pregnancy. Role of human chorionic gonadotrophin in the osmoregulatory changes of gestation. J Clin Invest 1988, 81:798-806.
103. Vokes T.P., Aycinena P.R., Robertson G.L. Effect of insulin on osmoregulation of vasopressin. Am J Physiol 1987, 252:E538-E548.
104. Durr J.A., Hoffman W.H., Hensen J., Sklar A.H., el Gammal T., Steinhart C.M. Osmoregulation of vasopressin in diabetic ketoacidosis. Am J Physiol 1990, 259:E723-E728.
105. Norsk P. Influence of low- and high-pressure baroreflexes on vasopressin release in humans. Acta Endocrinol (Copenh) 1989, 121:3-27.
106. Baylis P.H. Posterior pituitary function in health and disease. Clin Endocrinol Metab 1983, 12:747-770.
107. Robertson G.L. Thirst and vasopressin function in normal and disordered states of water balance. J Lab Clin Med 1983, 101:351-371.
108. Rowe J.W., Minaker K.L., Sparrow D., Robertson G.L. Age-related failure of volume-pressure-mediated vasopressin release. J Clin Endocrinol Metab 1982, 54:661-664.
109. Rolls B., Rolls E. Thirst (Problems in the behavioural sciences) 1982, Cambridge University Press, Cambridge, UK.
110. Fitzsimons J.T. Angiotensin, thirst, and sodium appetite. Physiol Rev 1998, 78:583-686.
111. Brooks V.L., Keil L.C., Reid I.A. Role of the renin-angiotensin system in the control of vasopressin secretion in conscious dogs. Circ Res 1986, 58:829-838.
112. Phillips P., Rolls B., Ledingham J., Morton J., Forsling M. Angiotensin II-induced thirst and vasopressin release in man. Clin Science 1985, 68:669-674.
113. Morton J., Connell J., Hughes M., Inglis G., Wallace E. The role of plasma osmolality, angiotensin II and dopamine in vasopressin release in man. Clin Endocrinol 1985, 23:129-138.
114. Nimura F., Labosky P., Kakuchi J., Okubo S., Yoshida H., Oikawa T., et al. Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. J Clin Invest 1995, 96:2947-2954.
115. Ito M., Oliverio M.I., Mannon P.J., Best C.F., Maeda N., Smithies O., et al. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Nat Acad Sci USA 1995, 92:3521-3525.
116. Sugaya T., Nishimatsu S., Tanimoto K., Takimoto E., Yamagishi T., Imamura K., et al. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J Biol Chem 1995, 270:18719-18722.
117. Hein L., Barsh G.S., Pratt R.E., Dzau V.J., Kobilka B.K. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice. Nature 1995, 377:744-747.
118. Martin R., Voigt K.H. Enkephalins co-exist with oxytocin and vasopressin in nerve terminals of rat neurohypophysis. Nature 1981, 289:502-504.
119. DeBodo R. The antidiuretic action of morphine and its mechanism. J Pharmacol Exp Ther 1944, 82:74-85.
120. Yamada K., Nakano M., Yoshida S. Inhibition of elevated arginine vasopressin secretion in response to osmotic stimulation and acute haemorrhage by U-62066E, a kappa-opioid receptor agonist. Br J Pharmacol 1990, 99:384-388.
121. Abelson J.L., Le Melledo J., Bichet D.G. Dose response of arginine vasopressin to the CCK-B agonist pentagastrin. Neuropsychopharmacology 2001, 24:161-169.
122. Wang H., Morris J.F. Constitutive nitric oxide synthase in hypothalami of normal and hereditary diabetes insipidus rats and mice: Role of nitric oxide in osmotic regulation and its mechanism. Endocrinology 1996, 137:1745-1751.
123. Raff H. Glucocorticoid inhibition of neurohypophysial vasopressin secretion. Am J Physiol 1987, 252:R635-R644.
124. Rowe J.W., Shelton R.L., Helderman J.H., Vestal R.E., Robertson G.L. Influence of the emetic reflex on vasopressin release in man. Kidney Int 1979, 16:729-735.
125. Zerbe R.L., Robertson G.L. A comparison of plasma vasopressin measurements with a standard indirect test in the differential diagnosis of polyuria. N Engl J Med 1981, 305:1539-1546.
126. Miller M., Dalakos T., Moses A.M., Fellerman H., Streeten D.H. Recognition of partial defects in antidiuretic hormone secretion. Ann Intern Med 1970, 73:721-729.
127. Fredriksson R., Lagerstrom M.C., Lundin L.G., Schioth H.B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 2003, 63:1256-1272.
128. Perez D.M. The evolutionarily triumphant G-protein-coupled receptor. Mol Pharmacol 2003, 63:1202-1205.
129. Topiol S., Sabio M. X-ray structure breakthroughs in the GPCR transmembrane region. Biochem Pharmacol 2009, 78:11-20.
130. Ostrowski N.L., Young W.S., Knepper M.A., Lolait S.T. Expression of vasopressin V1a and V2 receptor messenger ribonucleic acid in the liver and kidney of embryonic, developing, and adult rats. Endocrinol 1993, 133:1849-1859.
131. Ostrowski N.L., Lolait S.J., Young W.S. Cellular localization of vasopressin V1a receptor messenger ribonucleic acid in adult male rat brain, pineal, and brain vasculature. Endocrinol 1994, 135:1511-1528.
132. Sugimoto T., Saito M., Mochizuki S., Watanabe Y., Hashimoto S., Kawashima H. Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. J Biol Chem 1994, 269:27088-27092.
133. de Keyzer Y., Auzan C., Lenne F., Beldjord C., Thibonnier M., Bertagna X., et al. Cloning and characterization of the human V3 pituitary vasopressin receptor. FEBS Letts 1994, 356:215-220.
134. Lolait S.J., O'Carroll A.-M., Mahan L.C., Felder C.C., Button D.C., Young W.S., et al. Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Nat Acad Sci USA 1995, 92:6783-6787.
135. Serradeil-Le Gal C., Raufaste D., Derick S., Blankenstein J., Allen J., Pouzet B., et al. Biological characterization of rodent and human vasopressin V1b receptors using SSR-149415, a nonpeptide V1b receptor ligand. Am J Physiol Regul Integr Comp Physiol 2007, 293:R938-R949.
136. Grazzini E., Lodboerer A.M., Perez-Martin A., Joubert D., Guillon G. Molecular and functional characterization of V1b vasopressin receptor in rat adrenal medulla. Endocrinology 1996, 137:3906-3914.
137. Fenton R.A., Knepper M.A. Mouse models and the urinary concentrating mechanism in the new millennium. Physiol Rev 2007, 87:1083-1112.
138. Allison N.L., Albrightson-Winslow C.R., Brooks D.P., Stassen F.L., Huffman W.F., Stote R.M., et al. Species heterogeneity and antidiuretic hormone antagonists: What are the predictors?. Vasopressin: Cellular and Integrative Functions 1988, 207-214. Raven Press, New York. A.W.J. Cowley, J.F. Liard, D.A. Ausiello (Eds.).
139. Manning M., Stoev S., Chini B., Durroux T., Mouillac B., Guillon G. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res 2008, 170:473-512.
140. Decaux G., Soupart A., Vassart G. Non-peptide arginine-vasopressin antagonists: The vaptans. Lancet 2008, 371:1624-1632.
141. Berl, T. Quittnat-Pelletier, F. Verbalis, J. G. Schrier, R. W. Bichet, D. G. Ouyang, J. et al., Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 21 705-712.
142. Thibonnier M., Coles P., Thibonnier A., Shoham M. The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists. Annu Rev Pharmacol Toxicol 2001, 41:175-202.
143. Serradeil-Le Gal C., Wagnon J., Simiand J., Griebel G., Lacour C., Guillon G., et al. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-pheny l)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther 2002, 300:1122-1130.
144. Walum H., Westberg L., Henningsson S., Neiderhiser J.M., Reiss D., Igl W., et al. Genetic variation in the vasopressin receptor 1a gene (AVPR1A) associates with pair-bonding behavior in humans. Proc Nat Acad Sci USA 2008, 105:14153-14156.
145. Birnbaumer M., Seibold A., Gilbert S., Ishido M., Barberis C., Antaramian A., et al. Molecular cloning of the receptor for human antidiuretic hormone. Nature 1992, 357:333-335.
146. Seibold A., Brabet P., Rosenthal W., Birnbaumer M. Structure and chromosomal localization of the human antidiuretic hormone receptor gene. Am J Hum Genet 1992, 51:1078-1083.
147. Rehmann H., Wittinghofer A., Bos J.L. Capturing cyclic nucleotides in action: Snapshots from crystallographic studies. Nat Rev Mol Cell Biol 2007, 8:63-73.
148. Nielsen S., Frokiaer J., Marples D., Kwon T.H., Agre P., Knepper M.A. Aquaporins in the kidney: From molecules to medicine. Physiol Rev 2002, 82:205-244.
149. Boone M., Deen P.M. Physiology and pathophysiology of the vasopressin-regulated renal water reabsorption. Pflugers Arch 2008, 456:1005-1024.
150. Nedvetsky P.I., Tamma G., Beulshausen S., Valenti G., Rosenthal W., Klussmann E. Regulation of aquaporin-2 trafficking. Handb Exp Pharmacol 2009, 133-157.
151. Yang B., Bankir L., Gillespie A., Epstein C.J., Verkman A.S. Urea-selective concentrating defect in transgenic mice lacking urea transporter UT-B. J Biol Chem 2002, 277:10633-10637.
152. Smith C.P. Mammalian urea transporters. Exp Physiol 2009, 94:180-185.
153. Bankir L., Fernandes S., Bardoux P., Bouby N., Bichet D.G. Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans. J Am Soc Nephrol 2005, 16:1920-1928.
154. Morishita T., Tsutsui M., Shimokawa H., Sabanai K., Tasaki H., Suda O., et al. Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase isoforms. Proc Nat Acad Sci USA 2005, 102:10616-10621.
155. Fleming E.F., Athirakul K., Oliverio M.I., Key M., Goulet J., Koller B.H., et al. Urinary concentrating function in mice lacking EP3 receptors for prostaglandin E2. Am J Physiol 1998, 275:F955-F961.
156. Sands J.M., Naruse M., Baum M., Jo I., Hebert S.C., Brown E.M., et al. Apical extracellular calcium/polyvalent cation-sensing receptor regulates vasopressin-elicited water permeability in rat kidney inner medullary collecting duct. J Clin Invest 1997, 99:1399-1405.
157. Verbalis J.G., Robinson A.G., Moses A.M. Postoperative and post-traumatic diabetes insipidus. Frontiers of Hormone Research 1985, 247-265. S. Karger, Basel, Switzerland. P. Czernichow, A.G. Robinson (Eds.).
158. Olson B.R., Gumowski J., Rubino D., Oldfield E.H. Pathophysiology of hyponatremia after transsphenoidal pituitary surgery. J Neurosurg 1997, 87:499-507.
159. Nemergut E.C., Zuo Z., Jane J.A., Laws E.R. Predictors of diabetes insipidus after transsphenoidal surgery: A review of 881 patients. J Neurosurg 2005, 103:448-454.
160. Czernichow P., Pomarede R., Brauner R., Rappaport R. Neurogenic diabetes insipidus in children. Frontiers of Hormone Research 1985, 190-209. S. Karger, Basel, Switzerland. P. Czernichow, A.G. Robinson (Eds.).
161. Greger N.G., Kirkland R.T., Clayton G.W., Kirkland J.L. Central diabetes insipidus. 22 years' experience. Am J Dis Child 1986, 140:551-554.
162. Maghnie M., Cosi G., Genovese E., Manca-Bitti M.L., Cohen A., Zecca S., et al. Central diabetes insipidus in children and young adults. N Engl J Med 2000, 343:998-1007.
163. Moses A.M., Blumenthal S.A., Streeten D.H.P. Acid-base and electrolyte disorders associated with endocrine disease: Pituitary and thyroid. Fluid, Electrolyte and Acid-Base Disorders 1985, 851-892. Churchill Livingstone, New York. A.I. Arieff, R.A. De Fronzo (Eds.).
164. Fery F., Plat L., van de Borne P., Cogan E., Mockel J. Impaired counterregulation of glucose in a patient with hypothalamic sarcoidosis. N Engl J Med 1999, 340:852-856.
165. Odell W.D., Doggett R.S. Xanthoma disseminatum, a rare cause of diabetes insipidus. J Clin Endocrinol Metab 1993, 76:777-780.
166. Masera N., Grant D.B., Stanhope R., Preece M.A. Diabetes insipidus with impaired osmotic regulation in septo-optic dysplasia and agenesis of the corpus callosum. Arch Dis Child 1994, 70:51-53.
167. Imura H., Nakao K., Shimatsu A., Ogawa Y., Sando T., Fujisawa I., et al. Lymphocytic infundibuloneurohypophysitis as a cause of central diabetes insipidus. N Engl J Med 1993, 329:683-689.
168. Ahmed S.R., Aiello D.P., Page R., Hopper K., Towfighi J., Santen R.J. Necrotizing infundibulo-hypophysitis: A unique syndrome of diabetes insipidus and hypopituitarism. J Clin Endocrinol Metab 1993, 76:1499-1504.
169. Lacombe U.L. Imprimerie et Fonderie de Rignoux 1841, De la polydipsie, Paris, pp 87.
170. Weil A. Ueber die hereditare form des diabetes insipidus. Archives fur Pathologische Anatomie und Physiologie and fur Klinische Medicine (Virchow's Archives) 1884, 95:70-95.
171. Camerer J.W. Eine ergänzung des Weilschen diabetes-insipidus-stammbaumes. Archiv für Rassen-und Gesellschaftshygiene Biologie 1935, 28:382-385.
172. Dölle W. Eine weitere ergänzung des Weilschen diabetes-insipidus-stammbaumes. Zeitschrift für Menschliche Vererbungs-und Konstitutionslehre 1951, 30:372-374.
173. Weil A. Ueber die hereditare form des diabetes insipidus. Deutches Archiv fur Klinische Medizin 1908, 93:180-290.
174. Rittig R., Robertson G.L., Siggaard C., Kovacs L., Gregersen N., Nyborg J., et al. Identification of 13 new mutations in the vasopressin-neurophysin II gene in 17 kindreds with familial autosomal dominant neurohypophyseal diabetes insipidus. Am J Hum Genet 1996, 58:107-117.
175. Domenech E., Gomez-Zaera M., Nunes V. Study of the WFS1 gene and
176. Takeda K., Inoue H., Tanizawa Y., Matsuzaki Y., Oba J., Watanabe Y., et al. WFS1 (Wolfram syndrome 1) gene product: predominant subcellular localization to endoplasmic reticulum in cultured cells and neuronal expression in rat brain. Hum Mol Genet 2001, 10:477-484.
177. Ishihara H., Takeda S., Tamura A., Takahashi R., Yamaguchi S., Takei D., et al. Disruption of the WFS1 gene in mice causes progressive beta-cell loss and impaired stimulus-secretion coupling in insulin secretion. Hum Mol Genet 2004, 13:1159-1170.
178. Conlan A.R., Axelrod H.L., Cohen A.E., Abresch E.C., Zuris J., Yee D., et al. Crystal structure of Miner1: The redox-active 2Fe-2S protein causative in Wolfram Syndrome 2. J Mol Biol 2009, 392:143-153.
179. Howard R.L., Bichet D.G., Schrier R.W. Hypernatremic and polyuric states. The Kidney: Physiology and Pathophysiology 1992, 1753-1778. Raven Press, Ltd, New York. second ed. D.W. Seldin, G. Giebisch (Eds.).
180. Crowley R.K., Sherlock M., Agha A., Smith D., Thompson C.J. Clinical insights into adipsic diabetes insipidus: A large case series. Clin Endocrinol (Oxf) 2007, 66:475-482.
181. Fujiwara T.M., Bichet D.G. Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol 2005, 16:2836-2846.
182. Bichet D.G., Fujiwara T.M., et al. Nephrogenic diabetes insipidus. The Metabolic and Molecular Bases of Inherited Disease 2001, 4181-4204. McGraw-Hill, New York. eighth ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Vallee, B. Childs, K.W. Kinzler (Eds.).
183. Arthus M.-F., Lonergan M., Crumley M.J., Naumova A.K., Morin D., De Marco L., et al. Report of 33 novel AVPR2 mutations and analysis of 117 families with X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol 2000, 11:1044-1054.
184. Bichet D.G., Arthus M.-F., Lonergan M., Hendy G.N., Paradis A.J., Fujiwara T.M., et al. X-linked nephrogenic diabetes insipidus mutations in North America and the Hopewell hypothesis. J Clin Invest 1993, 92:1262-1268.
185. Perry T.L., Robinson G.C., Teasdale J.M., Hansen S. Concurrence of cystathioninuria, nephrogenic diabetes insipidus and severe anemia. N Engl J Med 1967, 276:721-725.
186. Arthus M.F., Lonergan M., Fujiwara T.M., Bichet D.G. Clinical and genetic approaches to the diagnosis of congenital polyuro-polydipsic syndromes 2004, The NDI Foundation 2004 Global Conference, Phoenix, Arizona, pp 55.
187. Spanakis E., Milord E., Gragnoli C. AVPR2 variants and mutations in nephrogenic diabetes insipidus: Review and missense mutation significance. J Cell Physiol 2008, 217:605-617.
188. Knops N.B., Bos K.K., Kerstjens M., van Dael K., Vos Y.J. Nephrogenic diabetes insipidus in a patient with L1 syndrome: A new report of a contiguous gene deletion syndrome including L1CAM and AVPR2. Am J Med Genet A 2008, 146A:1853-1858.
189. Fujimoto M., Imai K., Hirata K., Kashiwagi R., Morinishi Y., Kitazawa K., et al. Immunological profile in a family with nephrogenic diabetes insipidus with a novel 11 kb deletion in AVPR2 and ARHGAP4 genes. BMC Med Genet 2008, 9:42.
190. Bichet D.G., Birnbaumer M., Lonergan M., Arthus M.-F., Rosenthal W., Goodyer P., et al. Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus. Am J Hum Genet 1994, 55:278-286.
191. Arthus M.F., Lonergan M., Crumley M.J., Naumova A.K., Morin D., De Marco L.A., et al. Report of 33 novel AVPR2 mutations and analysis of 117 families with X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol 2000, 11:1044-1054.
192. Hobbs H.H., Russell D.W., Brown M.S., Goldstein J.L. The LDL receptor locus in familial hypercholesterolemia: Mutational analysis of a membrane protein. Annu Rev Genet 1990, 24:133-170.
193. Barak L.S., Salahpour A., Zhang X., Masri B., Sotnikova T.D., Ramsey A.J., et al. Pharmacological characterization of membrane-expressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor. Mol Pharmacol 2008, 74:585-594.
194. Morello J.P., Salahpour A., Laperrière A., Bernier V., Arthus M.-F., Lonergan M., et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 2000, 105:887-895.
195. Bernier V., Lagace M., Lonergan M., Arthus M.F., Bichet D.G., Bouvier M. Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. Mol Endocrinol 2004, 18:2074-2084.
196. Hermosilla R., Oueslati M., Donalies U., Schonenberger E., Krause E., Oksche A., et al. Disease-causing V(2) vasopressin receptors are retained in different compartments of the early secretory pathway. Traffic 2004, 5:993-1005.
197. Wuller S., Wiesner B., Loffler A., Furkert J., Krause G., Hermosilla R., et al. Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors. J Biol Chem 2004, 279:47254-47263.
198. Robben J.H., Sze M., Knoers N.V., Deen P.M. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: Relevance to therapy of nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 2007, 292:F253-F260.
199. Schoneberg T., Schulz A., Biebermann H., Hermsdorf T., Rompler H., Sangkuhl K. Mutant G-protein-coupled receptors as a cause of human diseases. Pharmacol Ther 2004, 104:173-206.
200. Romisch K. A cure for traffic jams: Small molecule chaperones in the endoplasmic reticulum. Traffic 2004, 5:815-820.
201. Conn P.M., Janovick J.A. Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease. Mol Cell Endocrinol 2009, 299:137-145.
202. Tamarappoo B.K., Verkman A.S. Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones. J Clin Invest 1998, 101:2257-2267.
203. Kunchaparty S., Palcso M., Berkman J., Velazquez H., Desir G.V., Bernstein P., et al. Defective processing and expression of thiazide-sensitive Na-Cl cotransporter as a cause of Gitelman's syndrome. Am J Physiol 1999, 277:F643-F649.
204. Peters M., Ermert S., Jeck N., Derst C., Pechmann U., Weber S., et al. Classification and rescue of ROMK mutations underlying hyperprostaglandin E syndrome/antenatal Bartter syndrome. Kidney Int 2003, 64:923-932.
205. Hayama A., Rai T., Sasaki S., Uchida S. Molecular mechanisms of Bartter syndrome caused by mutations in the BSND gene. Histochem Cell Biol 2003, 119:485-493.
206. Chillaron J., Estevez R., Samarzija I., Waldegger S., Testar X., Lang F., et al. An intracellular trafficking defect in type I cystinuria rBAT mutants M467T and M467K. J Biol Chem 1997, 272:9543-9549.
207. Bonnardeaux A., Bichet D.G. Inherited disorders of the renal tubule. Brenner & Rector's The Kidney 2004, 1697-1741. Saunders, Philadelphia. seventh ed. B.M. Brenner (Ed.).
208. Perucca J., Bichet D.G., Bardoux P., Bouby N., Bankir L. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. J Am Soc Nephrol 2008, 19:1721-1731.
209. Lomas D.A., Evans D.L., Finch J.T., Carrell R.W. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 1992, 357:605-607.
210. Lawless M.W., Greene C.M., Mulgrew A., Taggart C.C., O'Neill S.J., McElvaney N.G. Activation of endoplasmic reticulum-specific stress responses associated with the conformational disease Z alpha 1-antitrypsin deficiency. J Immunol 2004, 172:5722-5726.
211. Cohen F.E., Kelly J.W. Therapeutic approaches to protein-misfolding diseases. Nature 2003, 426:905-909.
212. Ulloa-Aguirre A., Janovick J.A., Brothers S.P., Conn P.M. Pharmacologic rescue of conformationally-defective proteins: Implications for the treatment of human disease. Traffic 2004, 5:821-837.
213. Barak L.S., Oakley R.H., Laporte S.A., Caron M.G. Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. Proc Nat Acad Sci USA 2001, 98:93-98.
214. Bernier V., Morello J.P., Zarruk A., Debrand N., Salahpour A., Lonergan M., et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol 2006, 17:232-243.
215. Glover D.J., Lipps H.J., Jans D.A. Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet 2005, 299-310.
216. Sangkuhl K., Schulz A., Rompler H., Yun J., Wess J., Schoneberg T. Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo. Hum Mol Genet 2004, 13:893-903.
217. Mankin A.S., Liebman S.W. Baby, don't stop!. Nat Genet 1999, 23:8-10.
218. Feldman B.J., Rosenthal S.M., Vargas G.A., Fenwick R.G., Huang E.A., Matsuda-Abedini M., et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 2005, 352:1884-1890.
219. Decaux G., Vandergheynst F., Bouko Y., Parma J., Vassart G., Vilain C. Nephrogenic syndrome of inappropriate antidiuresis in adults: High phenotypic variability in men and women from a large pedigree. J Am Soc Nephrol 2007, 18:606-612.
220. Soule S., Florkowski C., Potter H., Pattison D., Swan M., Hunt P., et al. Intermittent severe, symptomatic hyponatraemia due to the nephrogenic syndrome of inappropriate antidiuresis. Ann Clin Biochem 2008, 45:520-523.
221. Marcialis M.A., Faa V., Fanos V., Puddu M., Pintus M.C., Cao A., et al. Neonatal onset of nephrogenic syndrome of inappropriate antidiuresis. Pediatr Nephrol 2008, 23:2267-2271.
222. Kalenga K., Persu A., Goffin E., Lavenne-Pardonge E., van Cangh P.J., Bichet D.G., et al. Intrafamilial phenotype variability in nephrogenic diabetes insipidus. Am J Kidney Dis 2002, 39:737-743.
223. Kocan M., See H.B., Sampaio N.G., Eidne K.A., Feldman B.J., Pfleger K.D. Agonist-independent interactions between beta-arrestins and mutant vasopressin type II receptors associated with nephrogenic syndrome of inappropriate antidiuresis. Mol Endocrinol 2009, 23:559-571.
224. Brenner B., Seligsohn U., Hochberg Z. Normal response of factor VIII and von Willebrand factor to 1-deamino-8D-arginine vasopressin in nephrogenic diabetes insipidus. J Clin Endocrinol Metab 1988, 67:191-193.
225. Knoers N., Monnens L.A. A variant of nephrogenic diabetes insipidus: V2 receptor abnormality restricted to the kidney. Eur J Pediatr 1991, 150:370-373.
226. Langley J.M., Balfe J.W., Selander T., Ray P.N., Clarke J.T. Autosomal recessive inheritance of vasopressin-resistant diabetes insipidus. Am J Med Genet 1991, 38:90-94.
227. Deen P.M.T., Verdijk M.A.J., Knoers N.V.A.M., Wieringa B., Monnens L.A.H., van Os C.H., et al. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science 1994, 264:92-95.
228. Agre P. Aquaporin water channels (Nobel Lecture). Angew Chem Int Ed Engl 2004, 43:4278-4290.
229. Bichet D.G. Nephrogenic diabetes insipidus: New developments. Nephrology Self-Assessment Program 2004, 3:187-191.
230. Bichet D.G., Fujiwara T.M. Reabsorption of sodium chloride - lessons from the chloride channels. N Engl J Med 2004, 350:1281-1283.
231. Jeck N., Schlingmann K.P., Reinalter S.C., Komhoff M., Peters M., Waldegger S., et al. Salt handling in the distal nephron: Lessons learned from inherited human disorders. Am J Physiol Regul Integr Comp Physiol 2005, 288:R782-R795.
232. Peters M., Jeck N., Reinalter S., Leonhardt A., Tonshoff B., Klaus G.G., et al. Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies. Am J Med 2002, 112:183-190.
233. Marek S., Tekesin I., Hellmeyer L., Komhoff M., Seyberth H.W., Maier R.F., et al. [Differential diagnosis of a polyhydramnion in hyperprostaglandin E syndrome: A case report]. Z Geburtshilfe Neonatol 2004, 208:232-235.
234. Bockenhauer D., van't Hoff W., Lehnhardt A., Subtirelu M., Hildebrandt F., Bichet D.G. Secondary nephrogenic diabetes insipidus as a complication of inherited renal diseases. submitted 2010.
235. Boton R., Gaviria M., Batlle D.C. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis 1987, 10:329-345.
236. Grunfeld J.P., Rossier B.C. Lithium nephrotoxicity revisited. Nat Rev Nephrol 2009, 5:270-276.
237. Batlle D.C., von Riotte A.B., Gaviria M., Grupp M. Amelioration of polyuria by amiloride in patients receiving long-term lithium therapy. N Engl J Med 1985, 312:408-414.
238. Barlow E.D., de Wardener H.E. Compulsive water drinking. Q J Med New Series 1959, 28:235-258.
239. Robertson G.L. Dipsogenic diabetes insipidus: A newly recognized syndrome caused by a selective defect in the osmoregulation of thirst. Trans Assoc Am Physicians 1987, 100:241-249.
240. Amico J.A. Diabetes insipidus and pregnancy. Frontiers of Hormone Research 1985, 266-277. Karger, Basel, Switzerland. P. Czernichow, A.G. Robinson (Eds.).
241. Iwasaki Y., Oiso Y., Kondo K., Takagi S., Takatsuki K., Hasegawa H., et al. Aggravation of subclinical diabetes insipidus during pregnancy. N Engl J Med 1991, 324:522-526.
242. Forssman H. On hereditary diabetes insipidus, with special regard to a sex-linked form. Acta Med Scand 1945, 159:1-196.
243. Barron W.M., Cohen L.H., Ulland L.A., Lassiter W.E., Fulghum E.M., Emmanouel D., et al. Transient vasopressin-resistant diabetes insipidus of pregnancy. N Engl J Med 1984, 310:442-444.
244. Durr J.A., Hoggard J.G., Hunt J.M., Schrier R.W. Diabetes insipidus in pregnancy associated with abnormally high circulating vasopressinase activity. N Engl J Med 1987, 316:1070-1074.
245. Brewster U.C., Hayslett J.P. Diabetes insipidus in the third trimester of pregnancy. Obstet Gynecol 2005, 105:1173-1176.
246. Hiett A.K., Barton J.R. Diabetes insipidus associated with craniopharyngioma in pregnancy. Obstet Gynecol 1990, 76:982-984.
247. Lindheimer M.D. Polyuria and pregnancy: Its cause, its danger. Obstet Gynecol 2005, 105:1171-1172.
248. Leaf A. Neurogenic diabetes insipidus. Kidney Int 1979, 15:572-580.
249. Robertson G.L. Diagnosis of diabetes insipidus. Frontiers of Hormone Research 1985, 176-189. Karger, Basel. P. Czernichow, A.G. Robinson (Eds.).
250. Boyd S.D., Raz S., Ehrlich R.M. Diabetes insipidus and nonobstructive dilatation of urinary tract. Urology 1980, 16:266-269.
251. Gautier B., Thieblot P., Steg A. Mégauretère, mégavessie et diabète insipide familial. Sem Hop 1981, 57:60-61.
252. Bichet D. Nephrogenic diabetes insipidus. Oxford Textbook of Clinical Nephrology 1998, 1095-1109. Oxford University Press, New York. second ed. A. Davison, J. Cameron, J. Grunfeld, D. Kerr, E. Ritz, C. Winearls (Eds.).
253. Stern P., Valtin H. Verney was right, but. [editorial]. N Engl J Med 1981, 305:1581-1582.
254. Robertson G.L. Differential diagnosis of polyuria. Annu Rev Med 1988, 39:425-442.
255. Goldman M.B., Luchins D.J., Robertson G.L. Mechanisms of altered water metabolism in psychotic patients with polydipsia and hyponatremia. N Engl J Med 1988, 318:397-403.
256. Oksche A., Dickson J., Schülein R., Seyberth H.W., Müller M., Rascher W., et al. Two novel mutations in the vasopressin V2 receptor gene in patients with congenital nephrogenic diabetes insipidus. Biophys Biochem Res Com 1994, 205:552-557.
257. van Lieburg A.F., Verdijk M.A.J., Schoute F., Ligtenberg M.J.L., van Oost B.A., Waldhauser F., et al. Clinical phenotype of nephrogenic diabetes insipidus in females heterozygous for a vasopressin type 2 receptor mutation. Hum Genet 1995, 96:70-78.
258. Miller W.L. Molecular genetics of familial central diabetes insipidus. J Clin Endocrinol Metab 1993, 77:592-595.
259. Bichet D.G. Nephrogenic and central diabetes insipidus. Diseases of the Kidney 1997, Little, Brown and Company, New York, pp 2429-2449. sixth ed. R.W. Schrier, C.W. Gottschalk (Eds.).
260. Robertson G.L., Klein L.A., Roth J., Gorden P. Immunoassay of plasma vasopressin in man. Proc Nat Acad Sci USA 1970, 66:1298-1305.
261. Robertson G.L., Mahr E.A., Athar S., Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest 1973, 52:2340-2352.
262. Hartter E., Woloszczuk W. Radioimmunological determination of arginine vasopressin and human atrial natriuretic peptide after simultaneous extraction from plasma. J Clin Chem Clin Biochem 1986, 24:559-563.
263. LaRochelle F.T., North W.G., Stern P. A new extraction of arginine vasopressin from blood: The use of octadecasilyl-silica. Pflugers Arch 1980, 387:79-81.
264. Ysewijn-Van Brussel K.A., De Leenheer A.P. Development and evaluation of a radioimmunoassay for Arg8-vasopressin, after extraction with Sep-Pak C18. Clin Chem 1985, 31:861-863.
265. Preibisz J.J., Sealey J.E., Laragh J.H., Cody R.J., Weksler B.B. Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 1983, 5:I129-I138.
266. Seckl J.R., Dunger D.B., Bevan J.S., Nakasu Y., Chowdrey C., Burke C.W., et al. Vasopressin antagonist in early postoperative diabetes insipidus. Lancet 1990, 355:1353-1356.
267. Morgenthaler N.G., Struck J., Alonso C., Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006, 52:112-119.
268. Jochberger S., Velik-Salchner C., Mayr V.D., Luckner G., Wenzel V., Falkensammer G., et al. The vasopressin and copeptin response in patients with vasodilatory shock after cardiac surgery: A prospective, controlled study. Intensive Care Med 2009, 35:489-497.
269. Maas A.H., Siggaard-Andersen O., Weisberg H.F., Zijlstra W.G. Ion-selective electrodes for sodium and potassium: A new problem of what is measured and what should be reported. Clin Chem 1985, 31:482-485.
270. De Buyst J., Massa G., Christophe C., Tenoutasse S., Heinrichs C. Clinical, hormonal and imaging findings in 27 children with central diabetes insipidus. Eur J Pediatr 2007, 166:43-49.
271. Fujisawa I. Magnetic resonance imaging of the hypothalamic-neurohypophyseal system. J Neuroendocrinol 2004, 16:297-302.
272. Cattin F., Bonneville F., Chayep C., et al. Imagerie par resonnance magnetique du diabete insipide. Feuill Radiol 2005, 45:425-434.
273. Rappaport R. Magnetic resonance imaging in pituitary disease. Growth Genetics & Hormones 1995, 11:1-5.
274. Upadhyay A., Jaber B.L., Madias N.E. Epidemiology of hyponatremia. Semin Nephrol 2009, 29:227-238.
275. Decaux G. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Semin Nephrol 2009, 29:239-256.
276. Berl T., Anderson R.J., McDonald K.M., Schrier R.W. Clinical disorders of water metabolism. Kidney Int 1976, 10:117-132.
277. Bichet D.G., Kluge R., Howard R.L., Schrier R.W. Hyponatremic states. The Kidney: Physiology and Pathophysiology 1992, 1727-1751. Raven Press, New York. second ed. D.W. Seldin, G. Giebisch (Eds.).
278. Berl T. Psychosis and water balance [editorial]. N Engl J Med 1988, 318:441-442.
279. Verbalis J.G. The syndrome of inappropriate antidiuretic hormone secretion and other hypoosmolar disorders. Diseases of the Kidney 1997, 2393-2427. Little, Brown and Company, Boston. sixth ed. R.W. Schrier, C.W. Gottschalk (Eds.).
280. Schwartz W.B., Bennett W., Curelop S., Bartter F.C. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 1957, 23:529-542.
281. Berl T., Kumar S. Disorders of water metabolism. Comprehensive Clinical Nephrology 2000, 9.1-9.20. Mosby, London. R.J. Johnson, J. Feehally (Eds.).
282. Sausville E., Carney D., Battey J. The human vasopressin gene is linked to the oxytocin gene and is selectively expressed in a cultured lung cancer cell line. J Biol Chem 1985, 260:10236-10241.
283. Smitz S., Legros J.J., Franchimont P., le Maire M. Identification of vasopressin-like peptides in the plasma of a patient with the syndrome of inappropriate secretion of antidiuretic hormone and an oat cell carcinoma. Acta Endocrinol (Copenh) 1988, 119:567-574.
284. Verbalis J.G. Tumoral hyponatremia [editorial]. Arch Intern Med 1986, 146:1686-1687.
285. Schwaab G., Micheau C., Le Guillou C., Pacheco L., Marandas P., Domenge C., et al. Olfactory esthesioneuroma: A report of 40 cases. Laryngoscope 1988, 98:872-876.
286. Nolph K.D., Schrier R.W. Sodium, potassium and water metabolism in the syndrome of inappropriate antidiuretic hormone secretion. Am J Med 1970, 49:534-545.
287. Beck L.H. Hypouricemia in the syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med 1979, 301:528-530.
288. Falardeau P., Proulx J., Nawar T., Caron C., Montambault P., Plante G.E. Clinical and biochemical profiles of inappropriate secretion of antidiuretic hormone. Proceedings of the Seventh International Congress of Nephrology 1978, D-32.
289. Decaux G., Genette F., Mockel J. Hypouremia in the syndrome of inappropriate secretion of antidiuretic hormone. Ann Intern Med 1980, 93:716-717.
290. Manoogian C., Pandian M., Ehrlich L., Fisher D., Horton R. Plasma atrial natriuretic hormone levels in patients with the syndrome of inappropriate antidiuretic hormone secretion. J Clin Endocrinol Metab 1988, 67:571-575.
291. Kamoi K., Ebe T., Kobayashi O., Ishida M., Sato F., Arai O., et al. Atrial natriuretic peptide in patients with the syndrome of inappropriate antidiuretic hormone secretion and with diabetes insipidus. J Clin Endocrinol Metab 1990, 70:1385-1390.
292. Dillingham M.A., Anderson R.J. Inhibition of vasopressin action by atrial natriuretic factor. Science 1986, 231:1572-1573.
293. Nonoguchi H., Sands J.M., Knepper M.A. Atrial natriuretic factor inhibits vasopressin-stimulated osmotic water permeability in rat inner medullary collecting duct. J Clin Invest 1988, 82:1383-1390.
294. Zerbe R., Stropes L., Robertson G. Vasopressin function in the syndrome of inappropriate antidiuresis. Annu Rev Med 1980, 31:315-327.
295. Arieff A.I. Effects on the central nervous system of hypernatremic and hyponatremic states. Kidney Int 1976, 10:104-116.
296. Arieff A.I. Osmotic failure: Physiology and strategies for treatment. Hosp Pract (Off Ed) 1988, 23:173-178. 183-184, 187-189 passim.
297. Sterns R.H. Severe symptomatic hyponatremia: Treatment and outcome. A study of 64 cases. Ann Intern Med 1987, 107:656-664.
298. Berl T. Treating hyponatremia: Damned if we do and damned if we don't [clinical conference]. Kidney Int 1990, 37:1006-1018.
299. Sterns R.H., Nigwekar S.U., Hix J.K. The treatment of hyponatremia. Semin Nephrol 2009, 29:282-299.
300. Richter D., Schmale H. Molecular aspects of the expression of the vasopressin gene. Frontiers of Hormone Research 1985, 37-41. S. Karger, Basel. P. Czernichow, A.G. Robinson (Eds.).
301. Bourque C.W., Oliet S.H.R. Osmoreceptors in the central nervous system. Annu Rev Physiol 1997, 59:601-619.
302. Zerbe R.L., Robertson G.L. Disorders of ADH. Med North America 1984, 13:1570-1574.
303. Zerbe R.L., Henry D.P., Robertson G.L. Vasopressin response to orthostatic hypotension. Am J Med 1983, 74:265-271.
304. T.P. Vokes, G.L. Robertson, Physiology of secretion of vasopressin, in: P. Czernichow, A.G. Robinson (Eds.), Front Horm Res: Diabetes Insipidus in Man, Karger, 13 (1985) 127-155.
305. Gainer H., Chin H. Molecular diversity in neurosecretion: reflections on the hypothalamo-neurohypophysial system. Cell Mol Neurobiol 1998, 18:211-230.
306. Robertson G.L. The physiopathology of ADH secretion. Clinical Neuroendocrinology: A Pathophysiological Approach 1979, 247-260. Raven Press, New York. G. Tolis, F. Labrie, J.B. Martin, F. Naftolin (Eds.).
307. Cheng A., van Hoek A.N., Yeager M., Verkman A.S., Mitra A.K. Three-dimensional organization of a human water channel. Nature 1997, 387:627-630.
308. Baylis P.H. Vasopressin and its neurophysin. Endocrinology 1989, 213-229. W. B Saunders, Philadelphia. second ed. L.J. Degroot, J.M. Besser, G.F.J. Cahill, J.C. Marshall, D.H. Nelson, W.D. Odell (Eds.).
309. Sklar A.H., Schrier R.W. Central nervous system mediators of vasopressin release. Physiol Rev 1983, 63:1243-1280.
310. Robertson G.L. Diseases of the posterior pituitary. Endocrinology and Metabolism 1981, 251-277. McGraw-Hill, New York. D. Felig, J.D. Baxter, A.E. Broadus, L.A. Frohman (Eds.).